BriaCell Therapeutics Corp. will present two clinical data posters at the European Society for Medical Oncology (ESMO) Congress 2025...

Liminatus Pharma, a preclinical-stage biopharmaceutical company focused on cancer immunotherapy development, has partnered with Digital Offering LLC to explore...

CervoMed (NASDAQ: CRVO) will share 32-week primary endpoint results from the extension phase of its Phase 2b RewinD-LB study...

NextCure, Inc. announced preclinical data for NC605, an anti-Siglec-15 antibody, showing improved bone microarchitecture and reduced fractures in an...

Celcuity Inc. has initiated VIKTORIA-2, a Phase 3 clinical trial investigating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant...

Revolution Medicines announced the publication of research in •Science• detailing the discovery and development of zoldonrasib, a covalent inhibitor...

Unicycive Therapeutics announced positive results from a Phase 2 trial of its investigational phosphate binder, oxylanthanum carbonate (OLC), for...

Alumis, a late-stage biopharmaceutical company, has completed patient enrollment for its Phase 2b LUMUS trial of ESK-001, an oral...

Annexon, Inc. has completed enrollment in its Phase 3 ARCHER II trial for vonaprument, a drug targeting dry age-related...

Quanta Therapeutics appointed Vanessa L. Jacoby as Chief Business Officer and Chief Financial Officer, bringing over 25 years of...